Cardinal Health stock
CAHNYSECardinal Health, Inc., HealthcareISIN US14149Y1082
69Score 69 out of 100, Neutral
Price and trend
85 / 100
Price history
+35% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 24% above it.
Since September 2024 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 71).
The price is at its 52-week high. Largest decline in 20 years: 67% (April 2007 to September 2009).
Chart figures for advanced users
- SMA 50$242.88
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$224.42
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)71
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$182.50
- The lowest closing price of the last twelve months.
- Resistance$277.45
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Cardinal Health, Inc. belongs to the Medical (Distribution) industry (United States) and, with a market value of $64.13B, is number 3 of 17 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $254.25B (up 14.2% year on year) and earnings of $1.71B (up 9.8%).
- For fiscal 2027, analysts expect on average revenue of $266.29B (up 4.7%) and adjusted earnings per share of $12.83 (up 13.9%).
Show more
- MEQIRI Score 69 out of 100 (Neutral): rank 152 of 714 in Healthcare, median 53.
- The P/E is 35.6 (Medical (Distribution) median 26.9, own median of recent years 27.7).
- Our model puts fair value at $231.50, with the price 20% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 270% of earnings over the last 12 months.Fundamentals 78
- Reliable dividendNo dividend cut for over 39 years.Capital allocation 77
- Earnings per share growingUp 28.3% a year since 2021.Growth 83
Weaknesses
- Richly valuedP/E 35.6, Medical (Distribution) median 26.9, own median 27.7.Valuation 36
Its standout strengths are momentum and technical analysis, while profitability and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
What lowers it
- price near its 52-week high
- stable momentum
- solid fundamentals
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $178.08 and expensive above $330.72 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $253.27 (cash-flow model) and $209.73 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.9%. At 9.9% the fair value would be $212.07, at 7.9% it would be $260.43.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (26.9).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 10% on the twelve months before. Revenue has grown solidly since 2007, at about 6% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 4%, operating 1%, net 1%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 4 Feb 2027in 84 days
- Last reported
- 5 Nov 2026EPS reported $3.26 (expected $2.94)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $12.83+2.3%
- Revenue
- $266.29B+0.2%
- Earnings per share
- $14.29+1.5%
- Revenue
- $282.12B+0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −1.3%Fiscal 2027 guidance includes adjusted free cash flow of $3.5 billion to $4 billion and a reconfirmed segment profit of $200 million to $220 million, toward the lower end if the Iran conflict is protracted.
“We are reconfirming our previous GMPD segment profit guide of growing approximately $50 million off the ex IEEPA tariff refund fiscal '26 results with expected segment profit of $200 million to $220 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 11 Aug 2026 (fiscal Q4 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 7 insiders sold, $59.55M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Scherer Mary C.Sale
19 Aug 2026, Chief Accounting Officer
- Shares
- 2,302
- Price
- $237.39
- Value
- $546,473
- Hollar Jason M.Sale
19 Aug 2026, Chief Executive Officer
- Shares
- 44,529
- Price
- $236.18
- Value
- $10.52M
- Hollar Jason M.Sale
18 Aug 2026, Chief Executive Officer
- Shares
- 80,000
- Price
- $235.74
- Value
- $18.86M
Show 5 more
- Mason Stephen MSale
18 Aug 2026, CEO, GMPD Segment
- Shares
- 35,000
- Price
- $236.40
- Value
- $8.27M
- Weitzman DeborahSale
18 Aug 2026, CEO, PSS Segment
- Shares
- 7,354
- Price
- $235.45
- Value
- $1.73M
- Alt Aaron ESale
18 Aug 2026, Chief Financial Officer
- Shares
- 42,000
- Price
- $236.34
- Value
- $9.93M
- Mayer Jessica LSale
18 Aug 2026, Chief Legal/Compliance Officer
- Shares
- 29,436
- Price
- $236.19
- Value
- $6.95M
- Greene Michelle D.Sale
18 Aug 2026, Chief Information Officer
- Shares
- 11,650
- Price
- $235.72
- Value
- $2.75M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Cardinal Health
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 69
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Distribution)
The next larger and next smaller companies by market value
- McKessonMCK $124.67B76
- CencoraCOR $66.77B74
- Henry ScheinHSIC $9.77B66
- Shanghai Pharmaceuticals Holding601607.SS $9.01B53
- Sinopharm Group1099.HK $6.67B58
- GalenicaGALE.SW $5.42B60
- AmplifonAMP.MI $3.68B49
- Asker Healthcare GroupASKER.ST $2.87B61
ETFs that hold Cardinal Health
Held by 120 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 1.87% | 0.18% | €837.43M |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.93% | 0.15% | €592.11M |
| iShares Edge MSCI World Minimum Volatility Advanced UCITS ETF USD (Acc)MVEW | 0.89% | 0.30% | €306.37M |
Show 5 more
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.89% | 0.12% | €1.34B |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.88% | 0.15% | €3.27B |
| Invesco Global Active ESG Equity UCITS ETF USD AccIQSA | 0.72% | 0.30% | €3.12B |
| Xtrackers MSCI World Health Care UCITS ETF 1CXDWH | 0.68% | 0.25% | €4.18B |
| Deka MSCI USA MC UCITS ETFEL41 | 0.68% | 0.30% | €51.58M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Jun 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Jan 2024)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.